This inventor holds 1 USPTO granted patent. Top assignee: Lipoxen Technologies Incorporated. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Gregory Gregoriados: Innovator in Nucleic Acid Vaccination
Introduction
Gregory Gregoriados is a notable inventor based in London, GB. He has made significant contributions to the field of immunology, particularly in the development of innovative vaccination methods. His work focuses on enhancing immune responses through advanced compositions that utilize nucleic acids and assistor proteins.
Latest Patents
Gregoriados holds a patent for a method to enhance an immune response of nucleic acid vaccination. The patent describes a composition for the co-delivery to a cell of a nucleic acid and an assistor protein. This composition comprises vesicles, nucleic acid, and protein, wherein the nucleic acid operatively encodes an antigenic protein or a portion thereof that shares at least one epitope with the assistor protein. A preferred embodiment includes liposomes formed from liposome-forming materials, associated with the nucleic acid and assistor protein. This innovative composition is designed for use as a vaccine and provides an improved immune response compared to non-vesicular compositions.
Career Highlights
Gregory Gregoriados is associated with Lipoxen Technologies Incorporated, where he continues to advance his research and development efforts. His work has garnered attention for its potential to revolutionize vaccine efficacy and delivery methods.
Collaborations
Some of his notable coworkers include Andrew David Bacon and Peter Laing, who have collaborated with him on various projects within the field of immunology.
Conclusion
Gregory Gregoriados is a pioneering inventor whose work in nucleic acid vaccination holds promise for enhancing immune responses. His innovative approaches and collaborations contribute significantly to advancements in vaccine technology.